Neoadjuvant Inetetamab Plus Pyrotinib Phase II Trial for HER2-Positive Breast Cancer

Abstract This prospective multicenter single-arm phase II trial enrolled treatment-naive patients with stage II-III HER2-positive breast cancer to receive six cycles of neoadjuvant chemotherapy combined with the HER2-directed macromolecular agent Inetetamab and the tyrosine kinase inhibitor Pyrotinib. Between November 27, 2021, and December 18, 2025, 140 patients were enrolled, of whom 117 were evaluable for efficacy. The total pathologic complete response (tpCR; ypT0/is ypN0) rate was 61.5% (72/117; 95% CI, 52.6–70.5). The tpCR rate was significantly higher in hormone receptor (HR)-negative versus HR-positive tumors (76.2% vs 44.4%; odds ratio 0.25; 95% CI, 0.11–0.55; P < 0.001). The most common adverse events were anemia (89.2%), diarrhea (82.4%), and hypokalemia (47.3%), with grade ≥ 3 events including anemia, diarrhea, and leukopenia; no treatment-related deaths occurred. Neoadjuvant Inetetamab plus Pyrotinib with chemotherapy demonstrated clinically meaningful antitumor activity and a manageable safety profile in this population, supporting further randomized trials.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11513262/v1
Primary Topic
HER2/EGFR in Cancer Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Neoadjuvant Inetetamab Plus Pyrotinib Phase II Trial for HER2-Positive Breast Cancer

马兆生, Shengnan Yao, Ouchen Wang, Yinghao Wang et al.
4 links
Research Square
HER2/EGFR in Cancer Research
preprint

Neoadjuvant Inetetamab Plus Pyrotinib Phase II Trial for HER2-Positive Breast Cancer

马兆生, Shengnan Yao, Ouchen Wang, Yinghao Wang, Chaoyi Jiang, Weizhu Wu, Erjie Xia, Wenqian Wang, Min Zheng, Yiying Xu, Gui-Long Guo, Peipei Jiang, Jingao Dai, Jiatong Ru, Chenghui Yang, Duping Huang, Chaoyue Lv, Haiguang Liu, Hongye Hu, Wei Zhang, Yizi Zheng, Kuailu Lin, Xuanxuan Dai, Yupeng Liu, Quan Li, Weili Wu, Siyang Dong, Yizuo Chen, Xue Wu, Xiaoyang Li, Zhiqiang Ye, Shurong Zheng
preprint en

Abstract

Abstract This prospective multicenter single-arm phase II trial enrolled treatment-naive patients with stage II-III HER2-positive breast cancer to receive six cycles of neoadjuvant chemotherapy combined with the HER2-directed macromolecular agent Inetetamab and the tyrosine kinase inhibitor Pyrotinib. Between November 27, 2021, and December 18, 2025, 140 patients were enrolled, of whom 117 were evaluable for efficacy. The total pathologic complete response (tpCR; ypT0/is ypN0) rate was 61.5% (72/117; 95% CI, 52.6–70.5). The tpCR rate was significantly higher in hormone receptor (HR)-negative versus HR-positive tumors (76.2% vs 44.4%; odds ratio 0.25; 95% CI, 0.11–0.55; P < 0.001). The most common adverse events were anemia (89.2%), diarrhea (82.4%), and hypokalemia (47.3%), with grade ≥ 3 events including anemia, diarrhea, and leukopenia; no treatment-related deaths occurred. Neoadjuvant Inetetamab plus Pyrotinib with chemotherapy demonstrated clinically meaningful antitumor activity and a manageable safety profile in this population, supporting further randomized trials.

Research Square
Ningbo University (CN), Chinese Academy of Sciences (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Affiliated Hospital of Southwest Medical University (CN), Zhejiang Cancer Hospital (CN), Ruian People's Hospital (CN), Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN), Wenzhou Central Hospital (CN), Ningbo Medical Center Lihuili Hospital (CN)
Good health and well-being
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon